$GEVO

Ryan Christopher Michael sold $154K of GEVO

Ryan Christopher Michael (President & COO) sold 87,700 shares of Gevo, Inc. (GEVO) at $1.76 ($0.15M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ryan Christopher Michael
Published May 29, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GEVO
Neutral
medium confidence
Mentioned
$GEVO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEVONeutralLow
01

Why it matters

This provides a fresh, dated datapoint on insider behavior but does not introduce new fundamentals (no guidance, contracts, trials, or litigation).

02

Market read

Traders may monitor for follow-on insider activity or changes in ownership sentiment, but the 10b5-1 framing limits immediate fundamental read-through.

03

What to watch

The filing doesn’t reveal whether other insiders or large holders are changing positions around the same time; broader ownership/volume context could matter more than this single sale.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed May 29 for a May 27 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for Gevo, Inc. (GEVO).

Company-level read

Ticker impact

$GEVONeutralMedium confidence
Context

Gevo’s President & COO sold 87,700 shares in an open-market transaction disclosed via SEC Form 4 on May 27 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing provides a concrete datapoint (sale size, price, post-transaction holdings) but no new company-specific operating or financial catalyst. 10b5-1 reduces interpretive weight.

Market effects

Minimal; this is company-specific insider activity with no stated operational or sector catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • Gevo, Inc.

    Subject of the insider transaction disclosure; President & COO sold shares under a 10b5-1 plan.

  • Ryan Christopher Michael

    President & COO who executed the open-market sale of 87,700 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GEVOMedAI 8/10

Gevo (GEVO) Q2 2026 Earnings Call Transcript

Gevo (GEVO) reported Q2 2026 revenue of $47 million, up 7% year over year, and non-GAAP adjusted EBITDA of $11 million. Full-year 2026 adjusted EBITDA guidance is now above $60 million. The company targets $70 million of 45Z tax credit monetization in 2026 and recorded a $176 million noncash impairment tied to exiting its ATJ-60 project.

$GEVOHigh

Gevo, Inc. (GEVO): Results of Operations and Financial Condition

Gevo, Inc. (GEVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gevo Reports Second Quarter Results and Raises Financial Expectations for Full-Year 2026 ENGLEWOOD, Colo. – August 6, 2026 – Gevo, Inc. (NASDAQ: GEVO), a leader in renewable fuels, chemicals and carbon management, today announced its financial results for the second

$GEVOMedAI 8/10

Why Is Gevo (GEVO) Stock Rocketing Higher Today

Gevo (NASDAQ: GEVO) shares rose about 7.5% after the company said it expects 2026 non-GAAP Adjusted EBITDA to be more than double prior estimates. Gevo attributed the upgrade to new carbon pathways, higher production, and cost reductions, and it announced Todd Werpy, Ph.D., joining its board. The stock is volatile and trades at $1.68.